Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics

  • Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”)
  • CNM-Au8(R), Clene’s lead drug candidate, is a fundamentally new approach for treating the underlying factors contributing to ALS, MS, and PD, by restoring neuronal health and function
  • ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S.

Clene (NASDAQ: CLNN), a pioneering biopharmaceutical company, is making significant strides in the treatment of neurodegenerative diseases through its novel nanotherapeutic platform. With a mission to improve underlying mitochondrial health and protect neuronal function, Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”).

At the forefront of Clene’s innovations is CNM-Au8, a gold nanocrystal suspension currently in  development. CNM-Au8 is designed to act as a treatment for ALS, MS, and PD by restoring                neuronal health and function. The drug works by increasing cell energy production and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.